## APPENDIX 1

Country of residence of participants, country classification, and number of respondent per country

<table>
<thead>
<tr>
<th>Country</th>
<th>Geographical location</th>
<th>Classification</th>
<th>Number of respondents</th>
<th>Percentage of study population (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albania</td>
<td>Eastern Europe</td>
<td>LMIC</td>
<td>1</td>
<td>0.315457</td>
</tr>
<tr>
<td>Belarus</td>
<td>Eastern Europe</td>
<td>LMIC</td>
<td>10</td>
<td>3.154574</td>
</tr>
<tr>
<td>Belgium</td>
<td>Western Europe</td>
<td>HIC</td>
<td>102</td>
<td>32.17666</td>
</tr>
<tr>
<td>Brazil</td>
<td>Latin America</td>
<td>LMIC</td>
<td>89</td>
<td>28.07571</td>
</tr>
<tr>
<td>Burundi</td>
<td>Africa</td>
<td>LMIC</td>
<td>1</td>
<td>0.315457</td>
</tr>
<tr>
<td>Colombia</td>
<td>Latin America</td>
<td>LMIC</td>
<td>1</td>
<td>0.315457</td>
</tr>
<tr>
<td>Denmark</td>
<td>Western Europe</td>
<td>HIC</td>
<td>1</td>
<td>0.315457</td>
</tr>
<tr>
<td>Estonia</td>
<td>Eastern Europe</td>
<td>HIC</td>
<td>1</td>
<td>0.315457</td>
</tr>
<tr>
<td>France</td>
<td>Western Europe</td>
<td>HIC</td>
<td>12</td>
<td>3.785489</td>
</tr>
<tr>
<td>Georgia</td>
<td>Eastern Europe</td>
<td>LMIC</td>
<td>14</td>
<td>4.416404</td>
</tr>
<tr>
<td>Germany</td>
<td>Western Europe</td>
<td>HIC</td>
<td>4</td>
<td>1.26183</td>
</tr>
<tr>
<td>Greece</td>
<td>Western Europe</td>
<td>HIC</td>
<td>1</td>
<td>0.315457</td>
</tr>
<tr>
<td>Guadeloupe</td>
<td>Western Europe</td>
<td>HIC</td>
<td>1</td>
<td>0.315457</td>
</tr>
<tr>
<td>Ireland</td>
<td>Western Europe</td>
<td>HIC</td>
<td>1</td>
<td>0.315457</td>
</tr>
<tr>
<td>Italy</td>
<td>Western Europe</td>
<td>HIC</td>
<td>3</td>
<td>0.946372</td>
</tr>
<tr>
<td>Kazakhstan</td>
<td>Asia</td>
<td>LMIC</td>
<td>20</td>
<td>6.309148</td>
</tr>
<tr>
<td>Lebanon</td>
<td>Asia</td>
<td>LMIC</td>
<td>1</td>
<td>0.315457</td>
</tr>
<tr>
<td>Lithuania</td>
<td>Eastern Europe</td>
<td>HIC</td>
<td>1</td>
<td>0.315457</td>
</tr>
<tr>
<td>Luxembourg</td>
<td>Western Europe</td>
<td>HIC</td>
<td>1</td>
<td>0.315457</td>
</tr>
<tr>
<td>Malta</td>
<td>Western Europe</td>
<td>HIC</td>
<td>2</td>
<td>0.630915</td>
</tr>
<tr>
<td>Moldova</td>
<td>Eastern Europe</td>
<td>LMIC</td>
<td>1</td>
<td>0.315457</td>
</tr>
<tr>
<td>Morocco</td>
<td>Africa</td>
<td>LMIC</td>
<td>1</td>
<td>0.315457</td>
</tr>
<tr>
<td>Netherlands</td>
<td>Western Europe</td>
<td>HIC</td>
<td>4</td>
<td>1.26183</td>
</tr>
<tr>
<td>Portugal</td>
<td>Western Europe</td>
<td>HIC</td>
<td>6</td>
<td>1.892744</td>
</tr>
<tr>
<td>Romania</td>
<td>Eastern Europe</td>
<td>LMIC</td>
<td>2</td>
<td>0.630915</td>
</tr>
<tr>
<td>Russia</td>
<td>Eastern Europe</td>
<td>LMIC</td>
<td>20</td>
<td>6.309148</td>
</tr>
<tr>
<td>Slovenia</td>
<td>Eastern Europe</td>
<td>HIC</td>
<td>1</td>
<td>0.315457</td>
</tr>
<tr>
<td>Tajikistan</td>
<td>Asia</td>
<td>LMIC</td>
<td>1</td>
<td>0.315457</td>
</tr>
<tr>
<td>Thailand</td>
<td>Asia</td>
<td>LMIC</td>
<td>1</td>
<td>0.315457</td>
</tr>
<tr>
<td>Turkey</td>
<td>Western Europe</td>
<td>LMIC</td>
<td>2</td>
<td>0.630915</td>
</tr>
<tr>
<td>UK</td>
<td>Western Europe</td>
<td>HIC</td>
<td>3</td>
<td>0.946372</td>
</tr>
<tr>
<td>Ukraine</td>
<td>Eastern Europe</td>
<td>LMIC</td>
<td>8</td>
<td>2.523659</td>
</tr>
</tbody>
</table>


## APPENDIX 2

Comparison of PLWH residing in different continents

<table>
<thead>
<tr>
<th></th>
<th>Asia (n=23)</th>
<th>Europe (n=202)</th>
<th>Latin America (n=90)</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years: Mean (SD)</td>
<td>38.0 (9.67)</td>
<td>45.5 (12.0)</td>
<td>40.0 (10.3)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>CD4 count: Mean (SD)a</td>
<td>650 (151)</td>
<td>670 (314)</td>
<td>717 (389)</td>
<td>0.556</td>
</tr>
<tr>
<td>Anxiety disorders: n (%)</td>
<td>6 (26.1%)</td>
<td>43 (21.3%)</td>
<td>21 (23.3%)</td>
<td>0.833</td>
</tr>
<tr>
<td>Depression disorders: n (%)</td>
<td>5 (21.7%)</td>
<td>44 (21.8%)</td>
<td>24 (26.7%)</td>
<td>0.650</td>
</tr>
<tr>
<td>Adaptation of HIV care: n (%)</td>
<td>9 (39.1%)</td>
<td>55 (27.2%)</td>
<td>40 (44.4%)</td>
<td>0.012</td>
</tr>
<tr>
<td>ART interruption: n (%)</td>
<td>2 (8.7%)</td>
<td>8 (4.0%)</td>
<td>3 (3.4%)</td>
<td>0.456</td>
</tr>
<tr>
<td>Recreational substance use: n (%)</td>
<td>13 (56.5%)</td>
<td>137 (67.8%)</td>
<td>49 (54.4%)</td>
<td>0.072</td>
</tr>
<tr>
<td>Observe physical distancing: n (%)</td>
<td>19 (82.6%)</td>
<td>190 (94.1%)</td>
<td>74 (82.2%)</td>
<td>0.003</td>
</tr>
<tr>
<td>Face mask use: n (%)</td>
<td>21 (91.3%)</td>
<td>99 (49.0%)</td>
<td>88 (97.8%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Reported flu symptoms: n (%)</td>
<td>11 (47.8%)</td>
<td>95 (47.0%)</td>
<td>34 (37.8%)</td>
<td>0.321</td>
</tr>
<tr>
<td>Reported flu vaccination: n (%)</td>
<td>2 (8.7%)</td>
<td>113 (55.9%)</td>
<td>67 (74.4%)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

*a75 missing data

*Yates corrected Chi-Squared test or Kruskal Wallis test as appropriate
## APPENDIX 3

### Comparison of PLWH residing in Europe

<table>
<thead>
<tr>
<th></th>
<th>Western Europe (n=143)</th>
<th>Eastern Europe (n=59)</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years: Mean (SD)</td>
<td>47.6 (12.4)</td>
<td>40.6 (9.38)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Most recent CD4 count: Mean (SD)$^a$</td>
<td>679 (293)</td>
<td>656 (346)</td>
<td>0.672</td>
</tr>
<tr>
<td>Anxiety disorders: n (%)</td>
<td>25 (17.5%)</td>
<td>18 (30.5%)</td>
<td>0.062</td>
</tr>
<tr>
<td>Depression disorders: n (%)</td>
<td>27 (18.9%)</td>
<td>17 (28.8%)</td>
<td>0.171</td>
</tr>
<tr>
<td>Adaptation of HIV care: n (%)</td>
<td>35 (24.5%)</td>
<td>20 (33.9%)</td>
<td>0.232</td>
</tr>
<tr>
<td>ART interruption: n (%)</td>
<td>5 (3.6%)</td>
<td>3 (5.1%)</td>
<td>0.697</td>
</tr>
<tr>
<td>Recreational substance use: n (%)</td>
<td>100 (69.9%)</td>
<td>37 (62.7%)</td>
<td>0.405</td>
</tr>
<tr>
<td>Observe physical distancing: n (%)</td>
<td>135 (94.4%)</td>
<td>55 (93.2%)</td>
<td>0.749</td>
</tr>
<tr>
<td>Face mask use: n (%)</td>
<td>58 (40.6%)</td>
<td>41 (69.5%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Reported flu symptoms: n (%)</td>
<td>62 (43.4%)</td>
<td>33 (55.9%)</td>
<td>0.141</td>
</tr>
<tr>
<td>Reported flu vaccination: n (%)</td>
<td>88 (61.5%)</td>
<td>25 (42.4%)</td>
<td>0.019</td>
</tr>
</tbody>
</table>

$^a$52 missing data

*Yates corrected Chi-Squared test or Mann Whitney U test as appropriate
APPENDIX 4

Substance use among study participants

![Bar chart showing the number of PLWH using different substances.](image)

- Alcohol: 145
- Tobacco smoking: 98
- Marijuana: 41
- Cocaine: 16
- Vaping: 6
- Poppers: 4
- Crystal Meth: 4
- Mephedrone: 3
- Ecstasy: 2
- Amphetamine/Methamphetamine: 2
- Ketamine: 2
- GHB: 2
- Heroine: 1
- Methadone: 1
- LSD: 1
- GBL: 1

Number of PLWH
## APPENDIX 5

### Rationale for the inclusion of covariates in the multivariable analysis

<table>
<thead>
<tr>
<th>Category</th>
<th>Covariates</th>
<th>Reason for inclusion in model</th>
</tr>
</thead>
<tbody>
<tr>
<td>Socio-demographic</td>
<td>Age</td>
<td>Older age predisposes to symptoms</td>
</tr>
<tr>
<td></td>
<td>Sex</td>
<td>To account for different lifestyles / disease risks between males and females</td>
</tr>
<tr>
<td></td>
<td>LMIC / HIC residence</td>
<td>Different health settings / capacities</td>
</tr>
<tr>
<td>Preventive measures</td>
<td>Physical distancing</td>
<td>Reduced risk of COVID-19 and flu symptoms</td>
</tr>
<tr>
<td></td>
<td>Face mask use</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Recent flu vaccination</td>
<td>Reduced risk for flu-like illness</td>
</tr>
<tr>
<td>Treatment and care</td>
<td>Tenofovir treatment</td>
<td>Suspicion of effects on the coronavirus</td>
</tr>
<tr>
<td></td>
<td>Adaptation HIV care</td>
<td>Treatment interruption could affect the overall health and symptoms of PLWH</td>
</tr>
</tbody>
</table>

- *CD4 count excluded from final model (many missing values, and no association in bivariate analysis)*
- *Viral load not included in the model because it was detectable only in 17 participants, and there were several missing values.*
APPENDIX 6

COVID-19 infection questionnaire for persons living with HIV

We would like to learn from you the effects that COVID-19 (including the confinement measures implemented) may have on a person living with HIV. Please complete this anonymous survey which should not take longer than 10 minutes.

Section 1: General questions:

1. Age (in years): _______

2. Gender
   o Male
   o Female
   o Non-binary
   o Other

3. a. Which country do you currently live in? (country list)
   b. Which city do you currently live in? _________________

4. Maximum educational level:
   o Primary
   o Secondary
   o University undergraduate degree holder
   o University postgraduate degree holder

Section 2: General health issues

5. Have you been vaccinated against seasonal flu during the last 12 months?
   o Yes
   o No

6. Since January 2020 have you experienced a cold?
   o Yes
   o No

7. If yes, which symptoms did you experience? (multiple options possible)
   o Fever
   o Headache
   o Sore throat
   o Loss of taste
   o Stuffy and/or running nose
   o Loss of smell
   o Coughing
   o Shortness of breath
   o Muscle/body pain
   o General weakness
   o Nausea
   o Diarrhoea
8. If you experienced any of these symptoms, how long did the illness last (all symptoms considered)?
   o Less than one week
   o More than one week
   o Two or more weeks
   o Not applicable

9. If you experienced any of these symptoms, were you or are you hospitalised for this illness?
   o Yes
   o No
   o Not applicable

10. Have you been tested for COVID-19?
    o Yes
    o No

11. If yes, what was the result of the test?
    o Positive
    o Negative
    o Don’t know

If yes go to Q12, if no, skip to Q13

12. If you were positive for COVID-19:

Q13a Were you hospitalised at any stage?
   o Yes
   o No

Q13b If yes, how long were you hospitalised? ____ days

Q13c Did you receive breathing support at any stage?
   o Yes
   o No
   o Don’t know

13. If you were to suspect that you had COVID-19 symptoms, would you know who to contact for medical advice?
   o Yes
   o No

If yes go to Q14; if no skip to Q15

14. Who would you contact if you developed fever or cough?
   o The physician where I’m being followed up
   o A general practitioner
o Another doctor
o Other (specify): __________

15. As a person living with HIV, do you feel you are well informed about COVID-19 preventive measures and their impact on the continuity of your care (for example, provision of antiretroviral drugs, routine follow-up visits, etc)?
   o Yes
   o No

16. Over the last 2 weeks, how often have you been bothered by the following problems?

**GAD-2 score:**

Q17a. Little interest or pleasure in doing things
   o Not at all (0)
   o Several days (1)
   o More than half the days (2)
   o Nearly every day (3)

Q17b. Feeling down, depressed or hopeless
   o Not at all (0)
   o Several days (1)
   o More than half the days (2)
   o Nearly every day (3)

**PHQ-2 score:**

Q17c. Feeling nervous, anxious or on edge
   o Not at all (0)
   o Several days (1)
   o More than half the days (2)
   o Nearly every day (3)

Q17d. Not being able to stop or control worrying
   o Not at all (0)
   o Several days (1)
   o More than half the days (2)
   o Nearly every day (3)

**Section 3: HIV follow-up and treatment**

18. Have you visited a medical doctor or a health facility for your routine HIV follow-up during the last month?
   o Yes
   o No

19. When did you lastly do blood tests for HIV follow-up? (Month, year):
    ______________________

20. a. What was your last CD4 count? ___________________

    b. On what date (Month, year): _______________
21. a. Was your most recent viral load undetectable (less than 50 copies)?
   - Yes
   - No
   - Do not know / do not remember

   b. On what date (Month, year): ____________________________

22. Are you currently taking anti-HIV treatment?
   - Yes
   - No

   If yes go to Q23 and Q24; if no skip to Q25

23. Specify the anti-HIV treatment you take (name of medication, brand)
   ___________________________________________

24. Have you recently encountered challenges to consult your HIV physician or to obtain your anti-HIV medication due to the measures taken against the Covid-19 epidemic? (multiple options possible)
   - No, I have no problems getting my anti-HIV medication
   - Yes, I cannot have my drugs because they are not available at the clinic/pharmacy
   - Yes, I cannot go to the clinic/pharmacy due to mobility restrictions
   - Yes, I have no money to buy medications, since I stopped working because of Covid-19 restrictions
   - Other challenges (specify): _________________

25. Did you interrupt your anti-HIV medication at any point during the Covid-19 epidemic?
   - No
   - Yes
   - Don’t remember

26. During the Covid-19 epidemic, were you:
   - More likely to interrupt your anti-HIV medication?
   - Less likely to interrupt your anti-HIV medication?
   - As likely to interrupt your anti-HIV medication?

27. Did your HIV physician adapt your HIV care during the Covid-19 epidemic? (Multiple options possible)
   - No change
   - Yes, longer drug refills were given
   - Yes, the location for collecting my drugs was changed
   - Yes, some form of self-monitoring was used
   - Yes, phone consultations were provided
   - Yes, other (specify): __________________________

28. Do you take any other prescribed medication for other medical reasons?
   - Yes
No

29. If yes, please specify (drug name: _______; reason for prescription: _______)

30. Do you consume any of the recreational drugs listed below? (multiple options possible)
   - Alcohol
   - Tobacco
   - Vaping
   - Cocaine
   - Heroin
   - Marijuana
   - Other (specify): _____________
   - None

Section 4: COVID-19 Transmission and Prevention

31. How concerned are you that you may get infected by COVID-19?
   - Very concerned
   - Somewhat concerned
   - Not concerned

32. How concerned are you that you may infect a loved one with COVID-19?
   - Very concerned
   - Somewhat concerned
   - Not concerned

33. Which protective measure are you using? (multiple options possible)
   - I follow the 1.5-2m meters rule for social distancing
   - I wear a face mask when going outside
   - When I cough or sneeze, I cover mouth and nose with a paper tissue
   - When I cough or sneeze, I wash my hands shortly afterwards
   - I measure my body temperature at least twice every week
   - I wash my hands with soap and water many times a day
   - I use a hand sanitizer many times a day
   - I avoid touching my face (eyes, nose and mouth)

☐ I fully understand what this study is about, and I consent to participate. All the information I provide can be used by researchers to better understand coronavirus disease and its effect on persons living with HIV infection.

________________________________________________________________________

SUBMIT

Thank you very much for your participation.
Further information about Covid-19 and this research, please visit the website www.ICPcovid.com